Inhibiting tankyrase has been explored as a strategy to re-tune oncogenically dysregulated Wnt/β-catenin signalling in cancers with mutations in the tumour suppressor and destruction complex component APC (adenomatous polyposis coli)10,35–40. This evidence concerns the gene TNKS and neoplasm.